Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin analogue, petrelintide, in individuals with obesity or overweight and ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.